# A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

> **NCT03232593** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1758 (actual)

## Conditions studied

- Urothelial Carcinoma
- Carcinoma, Non-Small Cell Lung
- Small Cell Lung Carcinoma
- Triple Negative Breast Carcinoma
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03232593
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-29
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-08-12
- **Target enrollment:** 1758 (ACTUAL)
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03232593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03232593, "A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03232593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*